Download MendeleyDevelopment of HC-258, a Covalent Acrylamide TEAD Inhibitor That Reduces Gene Expression and Cell Migration.
Fnaiche, A., Chan, H.C., Paquin, A., Gonzalez Suarez, N., Vu, V., Li, F., Allali-Hassani, A., Cao, M.A., Szewczyk, M.M., Bolotokova, A., Allemand, F., Gelin, M., Barsyte-Lovejoy, D., Santhakumar, V., Vedadi, M., Guichou, J.F., Annabi, B., Gagnon, A.(2023) ACS Med Chem Lett 14: 1746-1753
- PubMed: 38116405
- DOI: https://doi.org/10.1021/acsmedchemlett.3c00386
- Primary Citation of Related Structures:
8PUX, 8PUY - PubMed Abstract:
The transcription factor YAP-TEAD is the downstream effector of the Hippo pathway which controls cell proliferation, apoptosis, tissue repair, and organ growth. Dysregulation of the Hippo pathway has been correlated with carcinogenic processes. A co-crystal structure of TEAD with its endogenous ligand palmitic acid (PA) as well as with flufenamic acid (FA) has been disclosed. Here we report the development of HC-258, which derives from FA and possesses an oxopentyl chain that mimics a molecule of PA as well as an acrylamide that reacts covalently with TEAD's cysteine. HC-258 reduces the CTGF , CYR61 , AXL , and NF2 transcript levels and inhibits the migration of MDA-MB-231 breast cancer cells. Co-crystallization with hTEAD2 confirmed that HC-258 binds within TEAD's PA pocket, where it forms a covalent bond with its cysteine.
Organizational Affiliation:
Département de Chimie, Université du Québec à Montréal, C.P. 8888, Succursale Centre-Ville, Montréal, Québec H3C 3P8, Canada.
